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INTRODUCTION
Due to recent advances in neonatal care, the chance
of survival for low birth weight infants has improved.
However, the prevalence of premature retinopathy
has increased. The first area of the retina affected by
premature retinopathy is the peripheral region, and
fundal examination using amydriatic drug is therefore
essential.
Systemic adverse reactions associated with the in-
stillation of mydriatic eyedrops include hypertension
and bradycardia (1, 2). However renal failure has not
been reported previously. This paper presents a case
of premature retinopathy who showed renal failure
after mydriatic tests.
CASE REPORT
Patient : A 29-day-old female weighing 674g. History
of present illness : InMay, 1999, super low birthweight
twins(690g) were delivered after 26 weeks and 3 days
of gestation. The patient was referred to our department
29 days after birth to undergo fundal examination.
Past medical history : On days 4 and 5 after birth,
indomethacin sodium was administered intravenously
to treat patent ductus arteriosus, and then the patient
suffered acute renal failure. Family medical history :
The other twin, an older brother, was also a super low
birth weight infant, weighing 964g. Findings on initial
examination : Fundal examinationwasperformedusing
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a mydriatic eyedrop (Mydrin-P). A broad circum-
ferential avascular zone was observed in both eyes,
and the patient was therefore diagnosed as premature
retinopathy. Course (Figure 1) : On day 36, thepatient
was diagnosed as stage 1, following the international
classification for premature retinopathy. On day 43,
clinical staging therefore advanced to stage 2. The
ocular fundi were difficult to examine clearly due to
poor mydriasis and hazy media.
On day 46, a thorough fundal examinationwas per-
formed by instilling more drops of a mydriatic drug
(Mydrin-P). On the next day, urine volume decreased.
On day 48, the patient’s general condition worsened
and the number of apneic episodes increased. Conse-
quently, the patient was placed on respiratorymanage-
ment by nasal continuous positive airway pressure
(NCPAP). Decreased urine volume was treated by
restricting water intake and administering a diuretic
drug and dopamine.
On day 50, further fundus examination was perfor-
med. Mydrin-P was again used and additional drops
were instilled during the examination. On day 51,
anuresis was confirmed and continuous dopamine
infusion was initiated following the diagnosis of acute
renal failure. A diuretic was administered intravenously
on several occasions. In addition, the patient was
intubated for artificial respirationmanagement to avoid
apnea. Since the patient experienced renal failure after
the instillation of Mydrin-P, excessive usage of the
mydriatic drops was suggested to be the cause. As
a result, in subsequent fundus examinations, the use
ofMydrin-Pwas restricted and the pupil was allowed to
dilate with time. The patient did not experience further
renal failure thereafter.
Several laser coagulation therapies improved clinical
staging of premature retinopathy to stage 3.
DISCUSSION
Mydriatic eyedrops are normally used for routine
fundus examination. Mydriasis is essential for prema-
ture retinopathy patients, since the periphery of the
ocular fundus needs to be examined.Mydriatic eyedrops
are roughly divided into two types : parasympathetic
blockers and sympathetic stimulants. The former di-
rectly or indirectly affects the pupillary sphinctermuscle,
whereas the latter directly or indirectly affects the pupil-
lary dilator muscle.
Commonly used drugs for mydriasis include: trop-
icamide, atropine, cyclopentolate (parasympathetic
blockers) and phenylephrine (sympathetic stimulant).
Figure１：Laboratory data, clinical stages and the management
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Mydrin-P is an eyedrop containing 0.5% tropicamide
and 0.5% phenylephrine hydrochloride. Since this is
a fast-acting and long-lasting drug, it is often utilized
in mydriasis tests.
Tropicamide is a muscarinic antagonist that exerts
little effect on the circulatory system. Althoughmydriatic
drugs have been shown to cause adverse reactions in
neonates and low birthweight infants suchasbradycardia,
few cases requiring special procedures have been re-
ported (3). Phenylephrine is a potent α1-adrenergic
receptor stimulant that acts on the cardiovascular
system to increase blood pressure, lower heart rate,
and constrict blood vessels in such organs as the kidney
and the extremities to reduce blood flow (4, 5). Phen-
ylephrine must therefore be administered with caution
to patients with heart diseases such as hypertension,
coronary disease or heart failure (6, 7).
Due to reports of bradycardia and apneic episodes,
caution should be exercised when usingMydrin-P
in low birth weight infants by close monitoring and
dilution of the drug as necessary (8).
Caputo et al. instilled10% phenylephrine in six neon-
ates, for a total of three timeswith fiveminute intervals.
They reported increases in systolic pressureby10mmHg
to 26mmHg and diastolic pressure by 2mmHg to 14
mmHg, while the heart rate decreased up to 20% in
four neonates (1).
Rosales et al. instilled 2.5% phenylephrine and 0.5%
tropicamide in ten low birth weight infants, weighing
less than 1600g, for a total of three times with five
minute intervals. An increase of greater than 20% in
systolic pressure was observed in eight patients and
an increase of greater than 50% was observed in three
of these eight patients (2). Compared with adults, the
effects of these drugs were reported to be greater in
neonates, especially low birth weight infants, and due
to immature cardiovascular and cerebrovascular sys-
tems, increased blood pressure ismore likely to induce
adverse reactions.
The development of the pupillary dilator muscle is
incomplete in neonates, and several instillations are
therefore necessary in dilating the pupil sufficiently
(3). The tendency is that the more severe the prema-
turity, the more difficult mydriasis (9). In the present
patient, the mydriatic drug was instilled many times
due to poor mydriasis. This caused the accumulation
of phenylephrine in the blood, constricting the renal
vessels and thus resulting in renal failure.
When amydriatic eyedrop is instilled, it entersnot only
the anterior chamber through the cornea, but also the
blood through the conjunctiva, and the nasal mucosa
and gastrointestinal tract through the nasolacrimal
canal (10). On some mydriatic drugs, about 80% of
administered dose is absorbed by the body (11). For
example, under normal condition, 80% of timolol instilled
to rabbits is absorbed by the body. Therefore, in order
to increase the concentration of amydriatic drug in the
eye by blocking the flow of the drug to the nasolacrimal
canal, compression of the lacrimal region and closure
of the eyelids are recommended.Whitson et al. instilled
10% phenylephrine and reported that bloodconcentration
20 minutes after the instillation could be reduced by
15-19% by closing the eyelids for oneminute (12).Most
neonates will close their eyes after instillation of a
mydriatic drug, but in the present patient, an eyelid
retractor was used to instill eyedrop containing phe-
nylephrine. As the result, the flow of this drug to the
nasolacrimal canal was elevated, and blood concentra-
tion of phenylephrine therefore became high enough
to cause renal failure.
Initially, we considered one possible explanation for
the renal failure as follows: The fundus examination
is very stressful for infants, and they sometimes ex-
perience apneic episodes after undergoing ophthalmol-
ogical examination. To ensure sufficient cerebral blood
flow after an apneic episode, the diving reflex constricts
peripheral blood vessels, and this could lead to renal
failure. However, assisted ventilation reduced the num-
ber of apneic episodes in the present patient when renal
failure was exacerbated, thus negating the potential
role of this possibility as the onset of renal failure.
The present patient was a low birth weight infant
with a history of renal failure.When eyedrops containing
0.5% phenylephrine were instilled several times to dilate
the pupil and the additional drops were instilled during
the examination using an eyelid retractor, the blood
concentration of the drug was elevated sufficiently
to contract the renal vessels, ultimately inducing renal
failure.
To the best of our knowledge, renal failure following
the instillation of mydriatic eyedrops has not previously
been reported. The present case suggests that since
the use of mydriatic eyedrops in low birthweight infants
could induce renal failure, the following points should
be borne in mind:1) Mydriatic eyedrops should be
used with the caution by monitoring mydriasis and
avoiding excessive instillation ; 2) After instillation,
the lacrimal region should be compressed to avoid the
flow of mydriatic drops to the nasolacrimal canal ;
and 3) Vital signs should be monitored to check the
onset of any adverse reactions for 12 hours after fundal
examination.
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